Additionally, since 2011, effective oncologic treatments have been available that significantly increase melanoma-specific survival—eg, immune checkpoint inhibitors and BRAF and MEK inhibitors.30,31,32,33,34 In the mortality analysis, we included those aged 60 years and older, and found no sign of a mortality decrease (Figure 3). This evidence concerns the gene BRAF and melanoma.